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Background: In many countries, nephrologists follow clinical practice guidelines for
mineral bone disorders to control secondary hyperparathyroidism (SHPT) associated
with abnormal serum calcium (Ca) and phosphorus (P) levels in patients undergoing
maintenance hemodialysis (MHD). The Kidney Disease Outcomes Quality Initiative
(KDOQI) Guidelines have long been used in Korea, and this study was undertaken to
investigate the current status of serum Ca and P control in MHD patients.
Methods: Data were collected from a total of 1,018 patients undergoing MHD
without intercurrent illness, in 17 hemodialysis centers throughout the country.
Serum levels of Ca, P, and intact parathyroid hormone (iPTH) were measured over
1 year, and the average values were retrospectively analyzed.
Results: Serum levels of Ca, P, and the CaP product were 9.170.7 mg/dL, 5.37
1.4 mg/dL, and 48.0713.6 mg2/dL2, respectively. However, the percentages of
patients with Ca, P, and Ca  P product levels within the KDOQI guideline ranges
were 58.7%, 51.0%, and 70.7%, respectively. Of the 1,018 patients, 270 (26.5%) had iPTH
4300 pg/mL (uncontrolled SHPT), whereas 435 patients (42.7%) showed iPTHn Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND
c-nd/4.0/).
al Medicine, Hanyang University College of Medicine, 222 Wangsimni-ro Seongdong-gu,
).
Kim et al / Serum mineral levels in HD patients 53o150 pg/mL. Patients with uncontrolled SHPT had signiﬁcantly higher values of
serum Ca, P, and CaP product than those with iPTH r300 pg/mL.
Conclusion: Despite the current clinical practice guidelines, SHPT seems to be
inadequately controlled in many MHD patients. Uncontrolled SHPT was associated
with higher levels of serum Ca, P, and Ca  P product, suggestive of the importance
of SHPT management.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Secondary hyperparathyroidism (SHPT) is a common com-
plication of chronic kidney disease (CKD). In addition, hyper-
phosphatemia has emerged as an important clinical issue in
dialysis patients over the past decade because higher levels of
serum phosphorus (P) and calcium–phosphorus (Ca P) pro-
duct have now been associated with increased vascular calci-
ﬁcation and cardiovascular mortality [1–6]. Similar to other
countries, the number of patients with end-stage renal disease
(ESRD) has been increasing in Korea. According to 2010
registry data from the Korean Society of Nephrology, hemo-
dialysis was the most frequently used renal replacement
therapy (in 39,509 patients) among the total 58,860 patients
with ESRD. Diabetes mellitus was the leading cause of ESRD
(45.2%), and cardiovascular disease was the major cause of
death (45%) in patients undergoing dialysis [7].
To improve the quality of care in patients undergoing main-
tenance hemodialysis, clinical practice guidelines have been
developed and used in many countries. Globally, including
Korea, the Kidney Disease Outcome Quality Initiative (KDOQI)
and Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines are popular [8,9]. In the Asia-Paciﬁc area, Australia
and Japan have their own guidelines for CKD-mineral bone
disorder (MBD) management (Caring for Australasians with
Renal Impairment [CARI] and Japanese Society for Dialysis
Therapy [JSDT] guidelines, respectively) [10,11]. In these guide-
lines, target ranges for serum minerals have been recommended
for the optimal management of patients undergoing MHD.
In Europe, America, and Japan, epidemiologic studies have
been conducted in patients with MHD and demonstrated
associations between abnormal mineral metabolism, based on
patient serum mineral levels and patient outcomes [12–14]. We
aimed to evaluate serum mineral levels in Korean patients
undergoing MHD to determine their relationship with para-
thyroid hormone control. These results may provide insight into
the status of current practice in the era of such guidelines.
Methods
Between January 1, 2009 and June 30, 2009, clinical data
were collected from patients undergoing MHD in 17 centers
(10 university hospitals and 7 secondary-care general hospi-
tals) in Korea. Enrollment criteria included (1) patient age
Z18 years, (2) chronic hemodialysis for Z6 months, and
(3) multiple measurements of serum Ca, P, and intact para-
thyroid hormone (iPTH) during the preceding 12 months.
Patients with intercurrent illnesses requiring hospitalization
were excluded. As a result, 1,018 patients were found to be
eligible among the 1,060 enrolled MHD patients. Patientconsent was obtained, as required by the institutional review
boards of the participating medical facilities.
Patient demographic and laboratory data were obtained by
reviewing medical records from 2008 to 2009. The laboratory
values were averaged because most centers measured serum
Ca and P monthly, and measured iPTH quarterly. Albumin-
corrected calcium (mg/dL) was calculated as [4 – albumin
(g/dL)]  0.8 þ total serum calcium (mg/dL) when the serum
albumin level was less than 4.0 g/dL. The iPTH concentration
was measured by second-generation PTH assays using four
different assay kits: Elecsys PTH (Roche Diagnostics; Meylan,
France), Immulite 2000 intact PTH (DPC; Los Angeles, USA),
ELISA-PTH (Schering-Cis Bio; Gif-sur-Yvette, France), and
Architect intact PTH (Abbott; Wiesbaden, Germany). Among
different second-generation PTH assays, our methods had a
relatively small interassay variability [15]. After data collection,
the distributions of serum mineral levels were examined,
based on the KDOQI guidelines.
Continuous data are presented as means 7 standard
deviation, and categorical variables are expressed as frequency
counts and percentages. Box plots are used for a visual
presentation of continuous variables; median, 75th, and 25th
percentiles, and ranges between the 10th to 90th percentile are
shown. The Kruskal-Wallis test was used to compare contin-
uous variables among three or more groups, and the Mann-
Whitney U test was used for comparisons between two
groups. The chi-square test and Pearson correlation efﬁciency
test were used to evaluate associations between categorical
and continuous variables, respectively. Statistical signiﬁcance
was deﬁned as P o 0.05.Results
General patient characteristics
Table 1 shows the general characteristics of the 1,018
patients. The mean age was 54 years, with an equal distribu-
tion by sex. In most patients, hemodialysis was performed
three times a week, in 4-hour sessions. Interestingly, 87.2% of
patients reported adherence to dietary phosphorus restric-
tions. Phosphorus binders were used by 72.3% of the study
participants and vitamin D receptor agonists were used by
45.9% of the participants. The former covered both calcium-
based and calcium-free phosphate binders (Table 2), and the
latter included calcitriol, paricalcitol, and alfacalcidol, in order
of the frequency of their use. Nevertheless, 270 patients
(26.5%) had iPTH 4300 pg/mL. Most of the patients used a
dialysate calcium concentration of 3.0 mEq/L. Fig. 1 illustrates
the distribution of dialysate calcium concentrations.
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The mean values of serum Ca, P, and CaP product were
9.170.7 mg/dL, 5.371.4 mg/dL, and 48.0713.6 mg2/dL2,
respectively. The mean iPTH level was 262.17298.8 pg/mL.
Fig. 2 illustrates the distributions of serum Ca, P, Ca  P
product, and iPTH levels, based on the recommended KDOQI
guideline ranges. Only approximately half of the patients were
considered within the guideline range for serum Ca (8.4–
9.5 mg/dL) and P (3.5–5.5 mg/dL). Uncontrolled hyperphospha-
temia and elevated Ca  P product levels (Z55mg2/dL2) were
observed in 40.7% and 29.3% of the patients, respectively. Only a
third of the patients were within the guideline range for iPTH
(150–300 pg/mL). Among patients outside the guideline range
for iPTH, more patients were considered to be in the low
(o150 pg/mL, 42.7%) than the high (4300 pg/mL, 26.5%) range.Serum levels of Ca, P, and Ca  P product by iPTH levels
Serum Ca, P, and Ca P product levels were compared by
iPTH levels (o150, 150–300, and 4300 pg/mL). As shown in
Fig. 3, serum Ca, P, and CaP product levels were signiﬁcantly
increased in patients with iPTH 4300 pg/mL, compared with
the other two groups. Patients with iPTH o150 pg/mL had
signiﬁcantly lower P and CaP product values than those with
iPTH levels in the 150–300 pg/mL range, although serum Ca
was not signiﬁcantly different between the two groups.Table 2. Serum mineral levels according to the current use of phosphate b
Serum parameters
Combined use
(n ¼ 306)
Calcium-b
(n ¼
Calcium (mg/dL) 9.070.6 9.07
Phosphorus (mg/dL) 5.971.1 4.77
Calcium-phosphorus product (mg2/dL2) 52.9710.4 41.77
iPTH (pg/mL) 262.67247.9 203.07
Data are described as mean7standard deviation.
Combined use, calcium-based phosphate bindersþcalcium-free phosphate b
n Comparisons were made using analysis of variance.
† Comparisons were made using the Kruskal-Wallis test.
Table 1. General patient characteristics (n ¼ 1,018)
Characteristics Values
Demographics
Age (y) 54.0713.3
Female, n (%) 507 (49.8)
Height (cm) 162.278.9
Weight (kg) 57.7710.6
BMI (kg/m2) 21.973.2
Hemodialysis
Vintage (y) 5.475.2
Frequency (times/wk) 3.070.2
Session length (h/wk) 11.970.6
Comorbidity
Diabetes mellitus, n (%) 378 (37.1)
Hypertension, n (%) 618 (60.7)
Management for SHPT
Dietary phosphorus restriction, n (%) 888 (87.2)
Phosphate binders, n (%) 736 (72.3)
Vitamin D receptor agonists, n (%) 429 (42.1)
Continuous variables are expressed as means7standard deviation.
BMI, body mass index; SHPT, secondary hyperparathyroidism.Among the 270 patients with iPTH levels 4300 pg/mL, 122
patients (45.2%) had serum Ca levels 49.5 mg/dL, whereas only
35 patients (13.0%) had serum Ca levels o8.4 mg/dL. In contrast,
of the 435 patients with iPTH levels o150 pg/mL, 90 patients
(20.7%) had serum Ca levels 49.5 mg/dL. Most of the patients
with iPTH levels 4300 pg/mL also had serum P (45.5 mg/dL,
63.0%) and CaP product (Z55 mg2/dL2, 53.7%) levels above the
guideline ranges. Consistent with these observations, the Pearson
correlation efﬁciency analysis revealed that the iPTH levels were
positively correlated with serum Ca (r2 ¼ 0.05, P o 0.0001),
P (r2 ¼ 0.08, P o 0.0001), and CaP product (r2 ¼ 0.11, P o
0.0001) levels. The iPTH level was also signiﬁcantly associated
with the vintage of hemodialysis (r2 ¼ 0.04, P o 0.0001).
Use of phosphate binders and vitamin D receptor agonists
Table 2 shows that serum Ca, P, and iPTH levels were
different according to the current use of phosphate binders.
As expected, there was a tendency to use calcium-based
binders and calcium-free agents in patients with rather low
and high serum calcium, respectively. Calcium-free phosphate
binders were used for the patients with a higher iPTH level.
The current use of vitamin D receptor agonists was sig-
niﬁcantly associated with iPTH levels (Table 3). Calcitriol and
paricalcitol were the major agents used for the patients with
iPTH levels 4300 pg/mL. Table 4 shows serum mineral levels217 patients
(21.3%)
675 patients
(66.3%)
126 patients 
(12.4%)
2.5 mEq/L 3.0 mEq/L 3.5 mEq/L
Figure 1. Distribution of dialysate calcium concentrations used in
patients.
inders
Phosphate binders P
ased agents
329)
Calcium-free agents
(n ¼ 101)
No use
(n ¼ 282)
0.6 9.670.9 9.270.9 o0.0001n
1.1 6.271.2 5.071.5 o0.0001n
10.3 59.5712.7 45.8715.7 o0.0001n
226.6 370.97315.5 291.37389.7 o0.0001†
inders; iPTH, intact-parathyroid hormone.
Figure 2. Distribution of serum calcium, phosphorus, calcium-phos-
phorus product, and intact parathyroid hormone (iPTH) levels,
classiﬁed by the ranges recommended in the KDOQI guidelines.
Figure 3. Comparisons of (A) serum calcium, (B) phosphorus, and
(C) calcium-phosphorus product, according to the different levels of
intact parathyroid hormone. Boxes are median and interquartile
ranges. Vertical lines represent the 10th to 90th percentile. nP o 0.05
using the Mann-Whitney U test.
Table 3. The current use of vitamin D receptor agonists by different
levels of intact parathyroid hormonen
Vitamin D receptor agonists iPTH (pg/mL)
o150
(n ¼ 435)
150300
(n ¼ 313)
4300
(n ¼ 270)
Alfacalcidol 19 (1.9) 28 (2.8) 10 (1.0)
Calcitriol 55 (5.4) 138 (13.6) 99 (9.7)
Paricalcitol 1 (0.1) 7 (0.7) 30 (3.0)
Alfacalcidolþcalcitriol 0 (0.0) 5 (0.5) 6 (0.6)
Paricalcitolþothers 0 (0.0) 13 (1.3) 56 (5.5)
No treatment 360 (35.4) 122 (12.0) 69 (6.8)
iPTH, intact parathyroid hormone.
n Value are presented as n (%). The association between the iPTH levels
and vitamin D receptor agonist types were signiﬁcant (P o 0.0001 by
chi-square test).
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nists. Although the serum P level did not differ among the
groups, serum Ca, Ca  P product, and iPTH levels showed
signiﬁcant differences, according to the use of the different
vitamin D receptor agonists. Paricalcitol was prescribed in the
patients with higher Ca and iPTH levels.
Discussion
The current study showed that relatively large percentages of
patients undergoing MHD were outside of the KDOQI guideline
target ranges for serum Ca, P, CaP product, and iPTH levels.
Thus, the percentages of our patients who were within the KDOQI
guideline ranges were relatively modest: Ca, 58.7%; P, 51.0%; CaP
product, 70.7%, and iPTH, 30.8%. These data may represent the
current status of serum mineral control in Korea because our
patients had demographic characteristics comparable to the over-
all Korean patient population undergoing MHD [7].
In this study, the percentage of patients who were within
the guideline ranges was a little larger than that observed in
the Dialysis Outcomes and Practice Patterns Studies (DOPPS I)
that was performed between 1996 and 2001, before the KDOQI
guidelines were published [8]. In DOPPS I, the percentages of
patients within the KDOQI guideline ranges were 40.5% for Ca,
40.8% for P, 56.6% for CaP product, and 21.4% for iPTH [12].
The percentages of patients within the KDOQI guideline ranges
in DOPPS II (2002–2004) were 42.5% for Ca, 44.4% for P, 61.4%
for the Ca  P product, and 26.2% for iPTH [12]. Further
improvements in these data were also reported in DOPPS III
(2005–2007) [13], which was performed after the KDOQI
Guidelines were published in 2003. Thus, a time factor may
be responsible for the differences between the DOPPS data and
the current ﬁndings. Whether or not the data were inﬂuenced
by differences in dietary phosphorus intake, medication use,
such as phosphate binders and vitamin D receptor agonists,
and dialysate calcium between the studies is unclear.In a similar context, the patients in the current study showed
better serum mineral proﬁles compared with individuals in
other DOPPS countries. A multicenter study from Italy reported
that serum P was 45.5 mg/dL in 51.6% and the CaP product
was 455 mg2/dL2 in 35.5% of the patients [14]. In a cohort
study in Japan (J-DOPPS), the mean values of serum Ca, P, CaP
Table 4. Serum mineral levels according to different vitamin D receptor agonists in patients with intact parathyroid hormone 4300 pg/mL
(n ¼ 270)
Serum parameters Alfacalcidol
(n ¼ 10)
Calcitriol
(n ¼ 99)
Paricalcitol
(n ¼ 30)
Alfacalcidolþ
Calcitriol
(n ¼ 6)
Paricalcitolþ
Others
(n ¼ 56)
Pn
Serum calcium (mg/dL) 8.770.5† 9.070.7† 10.170.7 9.370.8 9.770.7†,‡, § o0.0001
Serum phosphorous (mg/dL) 5.871.0 5.771.4 6.070.8 5.871.2 6.271.5 0.5450
Ca P product (mg2/dL2) 49.977.7† 51.4713.6† 60.579.3 54.1712.0 59.5715.4‡ 0.0004
iPTH (pg/mL) 496.07189.0 537.07331.0† 703.07373.0 496.07408.0 490.07260.0n 0.0112
Data are described as means7standard deviation.
CaP product, calcium-phosphorous product; iPTH, intact parathyroid hormone.
n Comparisons were made using the Kruskal-Wallis test.
† Comparison made using the Mann-Whitney U test with Bonferroni adjustment (P o 0.05) versus the paricalcitol group.
‡ Comparison made using the Mann-Whitney U test with Bonferroni adjustment (P o 0.05) versus the calcitriol group.
§ Comparison made using the Mann-Whitney U test with Bonferroni adjustment (P o 0.05) versus the alfacalcidol group.
Kidney Res Clin Pract 33 (2014) 52–5756product, and iPTH were 9.471.0 mg/dL, 5.771.6 mg/dL,
52.8715.9 mg2/dL2, and 1947263 pg/mL, respectively [16].
The percentages of patients with laboratory values within the
KDOQI guideline ranges were 44.2% for Ca, 43.1% for P, 58.9% for
CaP product, and 24.4% for iPTH in the J-DOPPS report.
Interestingly, in the current study, more patients had low
iPTH levels (o150 pg/mL, 42.7%) than high iPTH levels
(4300 pg/mL, 26.5%). This ﬁnding appears to be similar to
those from Western countries [12–14] and to correlate with
changes in the histological spectrum of uremic bone disease
over the past decades [17,18]; adynamic bone disease is
emerging as a major mineral disorder in patients undergoing
MHD [19]. Because oversuppression of PTH and excessive
calcium intake can induce adynamic bone disease [8], careful
use of vitamin D receptor agonists is required. Notably, the
new standard target range for iPTH in JSDT is between 60 and
240 pg/mL [11].
A high iPTH level was also found to be signiﬁcant because it
was associated with increased serum mineral levels. Serum Ca,
P, and the CaP product values correlated with iPTH and
signiﬁcantly increased in patients with iPTH levels 4300 pg/mL.
The positive correlation between serum P and iPTHmay be linked
to increased mortality [19], emphasizing the importance of SHPT
control.
Management of SHPT includes dietary phosphorus restric-
tion, use of phosphate binders, and adequate dialysis. The use of
vitamin D receptor agonists is another important tool for
suppressing PTH secretion. Consistent with this ﬁnding, the
current cross-sectional data showed that patients taking vita-
min D receptor agonists had lower serum P and CaP product
values. Serum mineral values were also compared among
patients taking three different vitamin D receptor agonists.
The observation that serum Ca and CaP product values were
lower in calcitriol users than in paricalcitol users was unex-
pected because hypercalcemia and hyperphosphatemia—side
effects associated with these types of drugs—have been more
common in those taking calcitriol, according to previous studies
[20–22]. This paradoxical ﬁnding may result from the cross-
sectional design of the current study. Hypercalcemia may have
been more frequent in patients medicated with paricalcitol
because paricalcitol is a second-line treatment that is only
allowed after calcitriol has been attempted, according to the
Korean National Health Insurance Service guidelines.
In summary, this study demonstrated the current status of
serum Ca, P, Ca P product, and parathyroid hormone control
in MHD patients. As international practice guidelines wereintroduced, serum mineral proﬁles appeared to improve.
However, relatively modest percentages of the patients remain
outside of the guideline’s target ranges. Because uncontrolled
secondary hyperparathyroidism (SHPT) was associated with
higher serum Ca, P, and Ca P product levels, adequate
treatment of SHPT may lead to reduced cardiovascular mor-
tality and improved patient outcomes.Conﬂicts of interest
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